<DOC>
	<DOCNO>NCT01039025</DOCNO>
	<brief_summary>To determine efficacy high-dose topotecan , cyclophosphamide melphalan patient Multiple Myeloma .</brief_summary>
	<brief_title>TMC ( Topotecan , Cyclophosphamide Melphalan ) Multiple Myeloma</brief_title>
	<detailed_description>Patients study catheter ( tube ) place vein collarbone . Most drug use study give catheter . Blood stem cell collect tube also . Before treatment start , patient complete physical exam , include blood urine test . A dentist perform dental exam either M.D . Anderson elsewhere . A chest x-ray bone x-rays do . An EKG heart scan do test heart function . A breathing test do . Patients also screen HIV Hepatitis . Blood stem cell collect patient white blood cell count normal . This early chemotherapy bone marrow growth factor ( G-CSF ) give . Collecting stem cell take 3 hour . It take 1 6 session get need amount cell . The process call apheresis . A machine attach catheter , blood drawn . The machine remove stem cell blood blood return body catheter . G-CSF injected skin twice day time stem cell collect . The stem cell store frozen use later help patient recover high-dose chemotherapy . After stem cell collect , patient receive high-dose chemotherapy . Cyclophosphamide give 2 hour Days 1 - 3 . Melphalan give Days 4 5 . Topotecan give 30 minute Days 1 - 5 , right cyclophosphamide melphalan . On Day 6 , drug give . On Day 7 , stem cell reinfused . G-CSF give day blood count return normal . Patients must stay hospital high-dose drug treatment . The length stay 3 week . Blood test do daily hospital , week first month . A bone marrow sample take Day 30 . Blood sample take 4 time first year year . Thyroid gland test bone marrow test do year . This investigational study . Cyclophosphamide , melphalan , topotecan approve FDA . Their use together study experimental . All participant enrol UTMDACC .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Patients intermediate high tumor mass multiple myeloma responsive primary refractory disease ; patient responsive refractory relapse . 2 . Physiological age &lt; /= 70 . 3 . Zubrod performance status &lt; 3 . 4 . Life expectancy great 12 week . 5 . Left ventricular ejection fraction &gt; /= 50 % . 6 . No uncontrolled arrythmias symptomatic cardiac disease . 7 . FEV1 , FVC DLCO &gt; /= 50 % . 8 . No symptomatic pulmonary disease . 9 . Serum creatinine &lt; 1.5 mg/dL . 10 . Serum bilirubin &lt; 2x upper limit normal . 11 . No evidence chronic active hepatitis cirrhosis . 12 . Patient pregnant . 13 . Patients guardian able sign inform consent . 14 . No active CNS disease . 15 . Platelet count &gt; 100K . 1 ) N/A</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Stem Cell Harvest</keyword>
	<keyword>Peripheral Blood Stem Cells</keyword>
</DOC>